Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Pre-Solicitation opportunity was posted on July 14, 2015. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Custom Conjugation of Anti-PD-1 Anti-body

Awarded
N02RC52617-76Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325413
New
DIBBS
CULTURE MEDIUM, THAYER-
Solicitation # SPE2DS-27-T-1066
Solicitation SPE2DS-27-T-1066 is a request for quotations issued by the DLA Troop Support Medical Supply Chain for the procurement of one package of Thayer-Martin Modified (MTM II) Agar culture medium, identified by NSN 6550-01-711-1542. This dark brown, ready-to-use plated medium is specifically designed for the isolation of pathogenic Neisseria from specimens containing mixed flora of bacteria and fungi. The product is delivered in packages of 100 plates and requires strict refrigeration storage between 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and must not be frozen. The contract mandates a non-extendable shelf life of three months, with a requirement that no more than 14 days elapse between the date of manufacture and the date of delivery to the government. Delivery is set for JBER, Alaska, with a required delivery date of October 27, 2026, under FOB Destination terms. Packaging must be commercial and sealed to prevent damage, with marking adhering to Medical Marking Standard No. 1 and shelf-life labels following MMS1C. Administrative requirements include electronic invoicing via the Wide Area WorkFlow system and compliance with various FAR and DFARS clauses, including the Buy American Act, Berry Amendment, and safeguarding of covered defense information. Evaluation will consider technical data for any alternate products offered and may include HUBZone price evaluation preferences. Inspection and acceptance will occur at the destination.
MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

1 day ago

DEADLINE

in 4 days
NAICS: 325413
New
Federal
6550--Optilite analyzer reagents
Solicitation # 36C26227Q0052
The Department of Veterans Affairs, Southern Arizona Healthcare System, is soliciting a Firm-Fixed Price Blanket Purchase Agreement under solicitation 36C26227Q0052 for the procurement of FDA-approved reference testing reagents and consumables validated for use on the Optilite analyzer. The scope includes specific items such as Freelite Kappa, Freelite Lambda, and Ceruloplasmin reagents, as well as TENCELL cuvettes and sample cups. To ensure system performance and safety, all materials must be manufactured by Binding Site Laboratories, and substitutions are prohibited. The contract is issued as a full and open competition under NAICS code 325413, with a total estimated period of performance of sixty months, consisting of a base period from November 9, 2026, to November 8, 2027, followed by four one-year option periods. The award will be granted to the responsible offeror whose proposal is most advantageous to the government, based on a technical acceptability review of the Statement of Work and the lowest price. Deliveries are required to be made to various VA Medical Centers across Arizona, California, and New Mexico, with standard orders delivered within four working days of placement. All shipments must be destination-based, with the vendor assuming all shipping costs and adhering to strict packaging standards to prevent damage. Invoicing is handled electronically through the Department of Veterans Affairs Financial Services Center in accordance with the Prompt Payment Act. Quotes must be submitted via email to Contract Specialist Carlos Magana by November 4, 2026.
262-NETWORK Contract Office 22 (36C262)

POSTED

3 days ago

DEADLINE

in 5 days
NAICS: 325413
New
Federal
BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
Solicitation # HT942627QE003
The Defense Health Agency is soliciting quotations to establish a Blanket Purchase Agreement (BPA) for the recurring resupply of consumable products for three Terumo Trima Accel Blood Collection Systems used by the USAISR Combat Casualty Care Research Team 1 in Texas. To maintain FDA approval and satisfy research protocols, the contractor must provide original manufacturer-supplied consumables, including Teruflex 500ml collection bags, Trima Platelet Kits, Isoplate Solution (PAS-F), TSCD Wafers, ACD-A Solution, and 150 mL couplers. This procurement is a 100 percent set-aside for Service-Disabled Veteran-Owned Small Businesses under NAICS 325413. The resulting BPA will have a 60-month ordering period with a total ceiling of 35 million dollars, though some documentation notes a lower limit of 350,000 dollars. Individual call orders are capped at 50,000 dollars, while Government Purchase Card orders are limited to 15,000 dollars. Awards will be made on a Lowest Price Technically Acceptable basis, with technical capability rated as pass or fail. All payment requests and receiving reports must be processed electronically through the Wide Area WorkFlow system. Quotations are due by November 6, 2026, and must be submitted in two separate volumes covering technical capability and pricing.
Army Medical Resources Acq Activity

POSTED

7 days ago

DEADLINE

in 7 days
NAICS: 325413
Federal
6550--VISN Cepheid GeneXpert Testing Supplies Base Plus 3 Op Yr RFQ
Solicitation # 36C24527Q0042
The Department of Veterans Affairs, specifically the VA North Atlantic Health Network (HSA 1.3), is soliciting a firm-fixed-price, Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Cepheid GeneXpert testing supplies. This requirement covers the procurement of FDA-approved reagents, consumables, and service for PCR analyzers to detect various pathogens, including CoV-2, Influenza, RSV, MRSA, and Mycobacterium Tuberculosis. The contract is structured with a base period ending October 31, 2027, and three subsequent one-year option periods extending through October 31, 2030. Deliveries will be made to multiple VA Medical Centers across Maryland, West Virginia, and Washington DC. This acquisition is set aside for HUBZone small businesses. Award will be determined using the Lowest Price Technically Acceptable (LPTA) method, evaluating technical acceptability, delivery performance, past performance, and price, with additional credit given to certified SDVOSB or VOSB offerors. Key contractor requirements include being an authorized distributor, acknowledging orders within 24 hours, and guaranteeing a minimum four-month expiration date on reagents. Additionally, the vendor must provide an emergency plan to deliver replacement supplies within 24 hours if products are found to be defective. Invoices must be submitted electronically, and payments will be processed in accordance with the Prompt Payment Act.
245-NETWORK Contract Office 5 (36C245)

POSTED

8 days ago

DEADLINE

in 6 days

AI Contract Overview

Show more

The National Cancer Institute's Center for Cancer Research Surgery Branch intends to award a sole source, firm fixed price contract to Miltenyi Biotec Inc. for the custom conjugation of a clinical grade anti-PD-1 antibody. This specialized service involves the activation of Phycoerythrin and the conjugation of 50 mg of the anti-PD-1 antibody Keytruda, including the provision of all conjugation protocols and reagent documentation. The procurement is essential for the development of novel cancer immunotherapies, specifically to support the isolation of T cell populations for the treatment of metastatic melanoma. The contract is processed under FAR Part 12 for commercial items and FAR Part 13 simplified acquisition procedures, with a delivery timeline of four to six weeks from the date of award. Miltenyi Biotec Inc. was selected as the sole source due to their proprietary labeling method, which is necessary to maintain the integrity of ongoing clinical studies. While this is not a request for competitive quotations, interested parties were given until July 27, 2015, to submit capability statements for consideration.

General Info

Agency

N/A

Contract Value

$27,806

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance

CA, USA

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseAwarded
Posted

Presolicitation

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts1 person available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Catherine MuirContracting Officer

Full Description

Show more
Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES Description: National Cancer Institute (NCI), Center for Cancer Research (CCR), Surgery Branch, plans to procure on a sole source basis the services for custom conjugation of anti-PD-1 antibody from Miltenyi Biotec Inc., 2303 Lindberg St, Auburn, CA, 95602-9562, UNITED STATES. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 352413 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price, type contract. The period of performance: delivery will be within four (4) to six (6) weeks from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The Surgery Branch of the National Cancer Institute is a combined laboratory and clinical research unit devoted to the development of innovative cancer immunotherapies and their translation to the treatment of patients with cancer. Initiatives include basic studies of cancer immunology and the conduct of clinical immunotherapy trials for patients with metastatic cancer. This procurement is needed to support the development of novel therapies in an attempt to cure many cancers including metastatic melanoma. Isolation of T cell populations with specific properties, both from tumor preparations (tumor-infiltrating lymphocytes) as well as peripheral blood could positively impact the efficacy of adoptive cell transfer therapies for the treatment of cancer, including metastatic melanoma. This procurement will allow the fluorescently conjugate the clinical grade anti-PD-1 antibody, which is vital to translate the Surgery Branch's findings in the lab to a clinical application. Contractor shall perform the following tasks: - Custom conjugation service of antibody of anti-PD1 antibody Keytruda o 50 mg of anti-PD1 antibody ? - Activation of PE (Phycoerythrin) ? - Preparation of the anti-PD1 antibody ? - Conjugation of anti-PD1 antibody to PE - Provide documentation of conjugation Protocol - Provide documentation of reagents used for conjugation This laboratory service is provided by Miltenyi Biotec Inc. The proposed source is the only laboratory that can perform the custom flurochrome conjungation of the anti-PD-1 antibody required by the Surgery Branch. This proposed source has developed a proprietary method to label antibodies that can be used to isolate cells for patient treatment. The performance characteristics and quality of the needed services, uniquely provided by the proposed Vendor, Miltenyi Biotec Inc., are required for maintaining the integrity of on-going studies, and a change would be disruptive to these studies. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 8:00AM EDT, on July 27, 2015. All responses and questions must be in writing and faxed +1 (555) 000-0000 or emailed to Catherine Muir, Contracting Officer via electronic mail at contact@example.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02RC52617-76 on all correspondence.

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS